A detailed history of Aqr Capital Management LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 696,797 shares of EGRX stock, worth $278,718. This represents 0.01% of its overall portfolio holdings.

Number of Shares
696,797
Previous 879,073 20.74%
Holding current value
$278,718
Previous $4.61 Million 15.28%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.34 - $5.6 $608,801 - $1.02 Million
-182,276 Reduced 20.74%
696,797 $3.9 Million
Q1 2024

May 15, 2024

BUY
$4.26 - $6.51 $1.64 Million - $2.51 Million
385,408 Added 78.07%
879,073 $4.61 Million
Q4 2023

Feb 14, 2024

BUY
$4.63 - $15.21 $975,573 - $3.2 Million
210,707 Added 74.47%
493,665 $2.58 Million
Q3 2023

Nov 14, 2023

SELL
$15.21 - $22.88 $1.29 Million - $1.95 Million
-85,015 Reduced 23.1%
282,958 $4.46 Million
Q2 2023

Aug 14, 2023

BUY
$17.74 - $31.87 $1.82 Million - $3.27 Million
102,553 Added 38.64%
367,973 $7.15 Million
Q1 2023

May 15, 2023

BUY
$25.06 - $34.09 $3.26 Million - $4.44 Million
130,105 Added 96.15%
265,420 $7.53 Million
Q4 2022

Feb 14, 2023

BUY
$24.98 - $39.77 $984,212 - $1.57 Million
39,400 Added 41.08%
135,315 $3.96 Million
Q3 2022

Nov 14, 2022

BUY
$26.42 - $47.12 $1.18 Million - $2.1 Million
44,599 Added 86.91%
95,915 $2.53 Million
Q2 2022

Aug 15, 2022

BUY
$41.26 - $51.35 $385,904 - $480,276
9,353 Added 22.29%
51,316 $2.28 Million
Q1 2022

May 16, 2022

SELL
$44.58 - $52.6 $234,579 - $276,781
-5,262 Reduced 11.14%
41,963 $2.08 Million
Q4 2021

Feb 14, 2022

SELL
$45.82 - $56.9 $9,576 - $11,892
-209 Reduced 0.44%
47,225 $2.41 Million
Q3 2021

Nov 15, 2021

SELL
$43.79 - $55.78 $362,274 - $461,467
-8,273 Reduced 14.85%
47,434 $2.65 Million
Q2 2021

Aug 16, 2021

SELL
$36.86 - $44.5 $210,175 - $253,739
-5,702 Reduced 9.29%
55,707 $2.38 Million
Q1 2021

May 17, 2021

BUY
$40.32 - $50.97 $674,311 - $852,422
16,724 Added 37.43%
61,409 $2.56 Million
Q4 2020

Feb 16, 2021

SELL
$41.72 - $51.34 $868,360 - $1.07 Million
-20,814 Reduced 31.78%
44,685 $2.08 Million
Q3 2020

Nov 16, 2020

SELL
$37.02 - $51.28 $988,434 - $1.37 Million
-26,700 Reduced 28.96%
65,499 $2.78 Million
Q2 2020

Aug 17, 2020

SELL
$43.24 - $55.02 $2.27 Million - $2.88 Million
-52,418 Reduced 36.25%
92,199 $4.42 Million
Q1 2020

May 15, 2020

BUY
$34.37 - $60.07 $588,448 - $1.03 Million
17,121 Added 13.43%
144,617 $6.65 Million
Q4 2019

Feb 14, 2020

BUY
$54.32 - $64.31 $771,072 - $912,880
14,195 Added 12.53%
127,496 $7.66 Million
Q3 2019

Nov 14, 2019

SELL
$53.25 - $59.98 $58,841 - $66,277
-1,105 Reduced 0.97%
113,301 $6.41 Million
Q2 2019

Aug 14, 2019

BUY
$46.61 - $58.45 $300,727 - $377,119
6,452 Added 5.98%
114,406 $6.37 Million
Q1 2019

May 14, 2019

BUY
$38.66 - $51.82 $406,664 - $545,094
10,519 Added 10.8%
107,954 $5.45 Million
Q4 2018

Feb 14, 2019

BUY
$36.72 - $67.73 $1.07 Million - $1.97 Million
29,091 Added 42.57%
97,435 $3.93 Million
Q3 2018

Nov 15, 2018

BUY
$66.65 - $83.86 $1.37 Million - $1.72 Million
20,549 Added 42.99%
68,344 $4.74 Million
Q2 2018

Aug 14, 2018

SELL
$51.25 - $76.62 $850,493 - $1.27 Million
-16,595 Reduced 25.77%
47,795 $3.62 Million
Q1 2018

May 15, 2018

SELL
$52.16 - $66.86 $4.93 Million - $6.32 Million
-94,479 Reduced 59.47%
64,390 $3.39 Million
Q4 2017

Feb 14, 2018

SELL
$49.6 - $60.87 $2.07 Million - $2.54 Million
-41,765 Reduced 20.82%
158,869 $8.49 Million
Q3 2017

Nov 14, 2017

BUY
$46.62 - $60.36 $9.35 Million - $12.1 Million
200,634
200,634 $12 Million

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $5.21M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.